1. Home
  2. FBIO vs PMN Comparison

FBIO vs PMN Comparison

Compare FBIO & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

HOLD

Current Price

$2.00

Market Cap

80.4M

Sector

Health Care

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

BUY

Current Price

$8.98

Market Cap

84.1M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
FBIO
PMN
Founded
2006
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.4M
84.1M
IPO Year
2011
2022

Fundamental Metrics

Financial Performance
Metric
FBIO
PMN
Price
$2.00
$8.98
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $42.90
AVG Volume (30 Days)
★ 261.5K
25.3K
Earning Date
11-13-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 97.40
N/A
EPS
★ 2.86
N/A
Revenue
★ $63,262,000.00
N/A
Revenue This Year
$24.55
N/A
Revenue Next Year
$43.73
N/A
P/E Ratio
$0.68
★ N/A
Revenue Growth
★ 9.69
N/A
52 Week Low
$1.83
$0.29
52 Week High
$4.53
$27.40

Technical Indicators

Market Signals
Indicator
FBIO
PMN
Relative Strength Index (RSI) 37.19 40.06
Support Level N/A $7.98
Resistance Level $2.17 $15.15
Average True Range (ATR) 0.08 0.76
MACD 0.02 0.10
Stochastic Oscillator 44.12 47.18

Price Performance

Historical Comparison
FBIO
PMN

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: